Personalizing Treatment for Patients with Non-small Cell Lung Cancer (NSCLC)

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Novartis.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, June 18, 2014 from 11:00 AM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from June 18, 2014 to December 18, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize current guideline recommendation for prevention, screening and risk assessment of patients with NSCLC
Understand the importance of matching patient characteristics to treatment choice in order to maximize treatment safety, tolerability and patient outcomes
Correlate genetic markers to specific treatment response that can be used to guide treatment selection in patients with NSCLC
Explain why adequate tissue samples and accurate pathology and genetic assessments are critical to treatment decisions-making
Summarize limitations of current treatment options, and the potential targets for new treatments
Summarize efficacy, safety, of emerging treatment options for NSCLC

INTENDED AUDIENCE
This activity is intended for medical and surgical oncologists, oncology nurses and other clinicians involved in the diagnosis and treatment of NSCLC.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Jyoti Patel, MD Has nothing to disclose.
Ajit S. Paintal, MD Speaker's Bureau: Cook Medical, Pfizer
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Bilal Piperdi, MD Speaker's Bureau: Genentech/Roche, Boehringer Ingelheim, Celgene, Merck
Consultant: Genentech/Roche
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advances in the Management of Renal Cell Carcinoma (RCC)

ACKNOWLEDGEMENT
This event is supported by PlatformQ Health Education, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 3.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Enduring Material
The enduring material will be available from June 25, 2014 to December 25, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Review the mechanisms of action of first-line therapies for RCC, advances in our understanding of RCC pathophysiology, and recently released clinical trial data for these therapies.
Select first-line therapies for advanced and metastatic RCC based on patient clinical characteristics, history of previous treatment, risk factors, co-morbidities, and other relevant considerations.
Assess for and manage treatment-related toxicities effectively when using systemic therapies in patients with advanced or metastatic RCC.
Evaluate recent research findings on molecular genetics and biomarkers that are likely to have future impacts on patient selection, prognostication, and monitoring of treatment efficacy in RCC.

INTENDED AUDIENCE
This activity is intended for medical oncologists, pathologists, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of RCC.

ESTIMATED TIME TO COMPLETE
This activity consists of three sessions, which should each take approximately 1 hour to complete, for a total of 3 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Lauren Harshman, MD Grant/Research: Pfizer, Astellas
Consultant: Pfizer, Dendreon
Sumanta Kumar Pal, MD Consultant: Novartis, Pfizer
Speaker's Bureau: Medivation
Toni Choueiri, MD Consultant: Novartis, Pfizer, Bayer
Laurence Albiges, MD, PhD Grant/Research: Novartis, Pfizer
Consultant: Novartis, Pfizer, Amgen, Sanofi
Naomi B. Haas, MD Consultant: Merck, BMS
Grant/Research: Novartis, GSK
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB,BS Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advancing the Management of Patients with Metastatic Melanoma

ACKNOWLEDGEMENT
This activity is supported by educational grants from Merck & Co., Inc., Genentech, and Bristol-Myers Squibb.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, July 22, 2014 from 11:00 AM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from July 22, 2014 to January 22, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Analyze clinical data evaluating the safety and efficacy of immunotherapies in the treatment of metastatic melanoma
Describe the mechanisms of action of new and emerging immunotherapeutic therapies for metastatic melanoma
Outline the various response patterns to immunotherapy and the related challenges in assessing response
Recognize and manage immune-related adverse events associated with immunotherapies for melanoma
Outline the role of BRAF/MEK/ERK pathway signaling in melanoma, and the development of inhibitors of this pathway
Describe the state of the science with respect to the role of alternate mutations seen in melanoma, such as NRAS, KIT, GNAQ, and GNA11
Outline new research directions in the treatment of metastatic melanoma
Apply individualized treatment strategies for a variety of patients with metastatic melanoma, including a patient with BRAF inhibitor resistance
Manage treatment-related adverse events associated with targeted therapies used in the treatment of metastatic melanoma

INTENDED AUDIENCE
This activity is intended for medical oncologists, dermatologists, surgical oncologists, pathologists, general surgeons, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of melanoma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Patrick Hwu, MD Has nothing to disclose.
Sapna Patel, MD Grant/Research: Bristol Meyers Squibb, Prometheus
Speaker's Bureau: Merck & Co.
Invited Speaker: Prometheus
Michael Davies, MD, PhD Grant/Research: GlaxoSmithKline, Genentech, Merck, Oncothyreon
Consultant: Sanofi Aventis, GlaxoSmithKline
Kevin Kim, MD Grant/Research: Genentech/Roche, Novartis
Consultant: Genentech/Roche, Novartis
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB,BS Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Evolving the Management of Multiple Myeloma

ACKNOWLEDGEMENT
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Bristol-Myers Squibb.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Friday, August 22, 2014 from 10:00 AM EST - 12:00 PM EST
Enduring Material
The enduring material will be available from August 22, 2014 to February 22, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Define smoldering multiple myeloma and describe the CRAB features commonly used for disease risk stratification, and its limitations
Summarize the new mSMART definition of patients with standard-risk, intermediate-risk, and high-risk multiple myeloma

INTENDED AUDIENCE
This activity is intended for hematologic oncologists, medical oncologists, pathologists, oncology nurses and pharmacists who manage patients with multiple myeloma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Kenneth Anderson, MD Consultant: Celgene, Onyx, Millennium, Gilead, Sanofi Aventis
Stockholder: Oncorp, Acetylon
Philip McCarthy, MD Consultant: Celgene, Janssen, Millennium, Sanofi
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, M.B., B.S Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Evidence-Based Management of Advanced and Metastatic Breast Cancer (MBC)

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Eisai.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, October 7, 2014 from 12:00 PM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from October 7, 2014 to April 7, 2015

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply current practice guidelines for the management of MBC
Select and initiate cytotoxic treatment options for patients with HER2-negative, hormone receptor-negative, or hormone-refractory MBC
Analyze recent clinical trial data on novel treatments and emerging therapies for the management of MBC

INTENDED AUDIENCE
Oncologists, oncology nurses and other clinicians involved in the diagnosis and treatment of breast cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of one session, which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Harold J. Burstein, MD, PhD Has nothing to disclose.
Erica L. Mayer, MD, MPH Grant/Research: Pfizer, Myriad, Eisai
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Joseph Sparano, MD  
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advances in the Management of Lymphoma and Chronic Lymphocytic Leukemia (CLL)

ACKNOWLEDGEMENT
This activity is supported by educational grants from Genentech, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, October 22, 2014 from 10:00 AM EST - 3:00 PM EST
Enduring Material
The enduring material will be available from October 22, 2014 to April 22, 2015

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Apply patient- and disease-specific factors in the selection of first-line, maintenance and relapsed therapy for patients with DLBCL
Identify prognostic and/or risk-stratification factors, including genetic markers, that may inform treatment decisions in patients with DLBCL
Outline new data on emerging treatment options for patients with NHL and their potential role in disease management
Describe the role of targeted biologic therapies in the management of patients with NHL
Formulate initial treatment criteria and select an initial treatment regimen for a patient with CLL
Identify the second treatment regimen for patients who may be progressing on/after initial FCR treatment
Apply an individualized approach to treatment selection for patients with CLL based on their prognosis, age, performance status, and comorbidities
Discuss current and emerging therapeutic management strategies for a patient with CLL who is older and who has comorbidities

INTENDED AUDIENCE
Hematologic oncologists, medical oncologists, pathologists, pharmacists, oncology nurses and other clinicians involved in the diagnosis and management of patients with lymphoma and chronic lymphocytic leukemia (CLL) are the target audience for this planned activity.

ESTIMATED TIME TO COMPLETE
The activity consists of four sessions, each of which should take approximately 1.0 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Andrew Zelenetz, MD, PhD Consultant: Celgene, Gilead, GSK, Hospira, Janssen, Amgen
Grant/Research: Gilead, GSK, Janssen
Andre Goy, Md, MS Consultant: Celgene
Speaker's Bureau: Pharmacyclics, Celgene, Millennium: The Takeda Oncology Company
Nicole Lamanna, MD Grant/Research: Gilead, Abbvie, Infinity Pharmaceuticals, Genentech
Consultant: Gilead, Genentech
Jennifer Brown, Md, PhD Consultant: GSK, Emergent, Morphosys, Celgene, Janssen, Pharmacyclics, Gilead, ProNai, Roche/Genentech, Kite Pharma
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, M.B., B.S Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Register Now


Click Here To Login